Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503566 | 1.00 | FUCA1 (0.56) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18477518 | 0.98 | FUCA1 (0.55) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14157507 | 0.96 | FUCA1 (0.56) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14157505 | 0.96 | FUCA1 (0.56) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL500532 | 0.96 | FUCA1 (0.56) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14157508 | 0.96 | FUCA1 (0.56) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL15082004 | 0.96 | FUCA1 (0.56) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11413096 | 0.92 | FUCA1 (0.60) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6182247 | 0.89 | HRH3 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL5116305 | 0.89 | HRH3 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| WO-2005030719-A1 | NOVEL METHOD FOR PREPARING CIS-OCTAHYDRO-ISOINDOLE | LES LABORATOIRES SERVIER (FR) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | AGTR2, AGTR1, BDKRB2 | FUCA1 4455/4885CYP1A2 1846/4885CYP3A4 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.